320 related articles for article (PubMed ID: 20217257)
1. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.
Modlin IM; Gustafsson BI; Moss SF; Pavel M; Tsolakis AV; Kidd M
Ann Surg Oncol; 2010 Sep; 17(9):2427-43. PubMed ID: 20217257
[TBL] [Abstract][Full Text] [Related]
2. Chromogranin A: is it a useful marker of neuroendocrine tumors?
Campana D; Nori F; Piscitelli L; Morselli-Labate AM; Pezzilli R; Corinaldesi R; Tomassetti P
J Clin Oncol; 2007 May; 25(15):1967-73. PubMed ID: 17513802
[TBL] [Abstract][Full Text] [Related]
3. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors.
Lawrence B; Gustafsson BI; Kidd M; Pavel M; Svejda B; Modlin IM
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):111-34, viii. PubMed ID: 21349414
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
[TBL] [Abstract][Full Text] [Related]
5. Plasma chromogranin a: concern on laboratory investigation.
Wiwanitkit V
Am J Gastroenterol; 2010 Dec; 105(12):2702; author reply 2702. PubMed ID: 21131937
[No Abstract] [Full Text] [Related]
6. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
Zatelli MC; Torta M; Leon A; Ambrosio MR; Gion M; Tomassetti P; De Braud F; Delle Fave G; Dogliotti L; degli Uberti EC;
Endocr Relat Cancer; 2007 Jun; 14(2):473-82. PubMed ID: 17639060
[TBL] [Abstract][Full Text] [Related]
7. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
8. Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.
Massironi S; Conte D; Sciola V; Spampatti MP; Ciafardini C; Valenti L; Rossi RE; Peracchi M
Am J Gastroenterol; 2010 Sep; 105(9):2072-8. PubMed ID: 20372113
[TBL] [Abstract][Full Text] [Related]
9. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
Singh S; Law C
Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):313-34. PubMed ID: 22646254
[TBL] [Abstract][Full Text] [Related]
10. Management of pancreatic neuroendocrine tumors.
Dabizzi E; Panossian A; Raimondo M
Minerva Gastroenterol Dietol; 2010 Dec; 56(4):467-79. PubMed ID: 21139544
[TBL] [Abstract][Full Text] [Related]
11. Plasma chromogranin A as marker for survival in patients with metastatic endocrine gastroenteropancreatic tumors.
Arnold R; Wilke A; Rinke A; Mayer C; Kann PH; Klose KJ; Scherag A; Hahmann M; Müller HH; Barth P
Clin Gastroenterol Hepatol; 2008 Jul; 6(7):820-7. PubMed ID: 18547872
[TBL] [Abstract][Full Text] [Related]
12. [Chromogranin A and neuroendocrine tumors].
Díaz Pérez JÁ; Currás Freixes M
Endocrinol Nutr; 2013; 60(7):386-95. PubMed ID: 23271036
[TBL] [Abstract][Full Text] [Related]
13. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
14. Measurements of chromogranin B can serve as a complement to chromogranin A.
Stridsberg M; Eriksson B; Fellström B; Kristiansson G; Tiensuu Janson E
Regul Pept; 2007 Mar; 139(1-3):80-3. PubMed ID: 17116339
[TBL] [Abstract][Full Text] [Related]
15. Is the combination of chromogranin A and pancreatic polypeptide serum determinations of interest in the diagnosis and follow-up of gastro-entero-pancreatic neuroendocrine tumours?
Walter T; Chardon L; Chopin-laly X; Raverot V; Caffin AG; Chayvialle JA; Scoazec JY; Lombard-Bohas C
Eur J Cancer; 2012 Aug; 48(12):1766-73. PubMed ID: 22133573
[TBL] [Abstract][Full Text] [Related]
16. Biochemical diagnosis of neuroendocrine GEP tumor.
Oberg K
Yale J Biol Med; 1997; 70(5-6):501-8. PubMed ID: 9825477
[TBL] [Abstract][Full Text] [Related]
17. Serum pancreastatin: the next predictive neuroendocrine tumor marker.
Rustagi S; Warner RR; Divino CM
J Surg Oncol; 2013 Aug; 108(2):126-8. PubMed ID: 23775817
[TBL] [Abstract][Full Text] [Related]
18. Limitations of Chromogranin A in clinical practice.
Marotta V; Nuzzo V; Ferrara T; Zuccoli A; Masone M; Nocerino L; Del Prete M; Marciello F; Ramundo V; Lombardi G; Vitale M; Colao A; Faggiano A
Biomarkers; 2012 Mar; 17(2):186-91. PubMed ID: 22303881
[TBL] [Abstract][Full Text] [Related]
19. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A.
Popovici T; Moreira B; Schlageter MH; Bories PN
Clin Biochem; 2014 Jan; 47(1-2):87-91. PubMed ID: 24201067
[TBL] [Abstract][Full Text] [Related]
20. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]